產(chǎn)品描述: | Sacubitrilat (Desethyl Sacubitril) is an active neprilysin (NEP) inhibitor. |
靶點: |
Neprilysin |
體外研究: |
Sacubitrilat (LBQ657) is a single diastereomer with specific stereocenters. Sacubitrilat is bound to the active site of NEP by an intricate network of interactions that involves all functional groups of the compound giving rise to the high inhibitory potency of 5?nM |
體內(nèi)研究: |
Pharmacokinetics of Sacubitril, Sacubitrilat (LBQ657), and valsartan following the administration of single oral doses of LCZ696 400 or 1200 mg under fasting condition are summarized. The mean plasma concentrations of Sacubitril increases rapidly with a median Tmax?of 0.52 h for the 400 mg dose and 1.05 h for the 1200 mg dose, followed by Sacubitrilat, with the corresponding Tmax?values of 2.07 and 3.05 h, respectively. The median Tmax?for valsartan is 2.07 h for both the LCZ696 400 mg and 1200 mg doses. The Cmax?of Sacubitrilat shows a dose proportional increase, while the Cmax?of Sacubitril and Valsartan shows less than proportional increases between the doses. The arithmetic mean AUC0-24 h?and AUClast?for Sacubitril and Sacubitrilat increases approximately dose proportionally, but shows less than dose proportional increase for Valsartan |
參考文獻: |
1. Schiering N, et al. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci Rep. 2016 Jun 15;6:27909. 2. Langenickel TH, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. Eur J Clin Pharmacol. 2016 Aug;72(8):917-24. |
溶解性: |
Soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.608 ml |
13.04 ml |
26.08 ml |
5 mM |
0.522 ml |
2.608 ml |
5.216 ml |
10 mM |
0.261 ml |
1.304 ml |
2.608 ml |
50 mM |
0.052 ml |
0.261 ml |
0.522 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |